HK1131626A1 - Antibodies and immunoconjugates and uses therefor - Google Patents

Antibodies and immunoconjugates and uses therefor

Info

Publication number
HK1131626A1
HK1131626A1 HK09110356.8A HK09110356A HK1131626A1 HK 1131626 A1 HK1131626 A1 HK 1131626A1 HK 09110356 A HK09110356 A HK 09110356A HK 1131626 A1 HK1131626 A1 HK 1131626A1
Authority
HK
Hong Kong
Prior art keywords
immunoconjugates
antibodies
uses therefor
therefor
steap
Prior art date
Application number
HK09110356.8A
Other languages
English (en)
Inventor
Mark S Dennis
Bonnee Rubinfeld
Paul Polakis
Aya Jakobovits
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of HK1131626A1 publication Critical patent/HK1131626A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
HK09110356.8A 2006-10-27 2009-11-06 Antibodies and immunoconjugates and uses therefor HK1131626A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US86329506P 2006-10-27 2006-10-27
US86870706P 2006-12-05 2006-12-05
US92130007P 2007-03-30 2007-03-30
US93785707P 2007-06-29 2007-06-29
PCT/US2007/082726 WO2008052187A2 (en) 2006-10-27 2007-10-26 Antibodies and immunoconjugates and uses therefor

Publications (1)

Publication Number Publication Date
HK1131626A1 true HK1131626A1 (en) 2010-01-29

Family

ID=39165835

Family Applications (3)

Application Number Title Priority Date Filing Date
HK13100563.2A HK1173161A1 (en) 2006-10-27 2009-11-06 Antibodies and immunoconjugates and uses therefor
HK09110356.8A HK1131626A1 (en) 2006-10-27 2009-11-06 Antibodies and immunoconjugates and uses therefor
HK15108753.3A HK1208228A1 (en) 2006-10-27 2015-09-08 Antibodies and immunoconjugates and uses therefor

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK13100563.2A HK1173161A1 (en) 2006-10-27 2009-11-06 Antibodies and immunoconjugates and uses therefor

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK15108753.3A HK1208228A1 (en) 2006-10-27 2015-09-08 Antibodies and immunoconjugates and uses therefor

Country Status (30)

Country Link
US (5) US8436147B2 (pl)
EP (3) EP2061814B1 (pl)
KR (2) KR101541550B1 (pl)
AR (1) AR063532A1 (pl)
AU (1) AU2007308792B2 (pl)
BR (1) BRPI0717638A2 (pl)
CA (1) CA2667019C (pl)
CO (1) CO6180431A2 (pl)
CR (1) CR10734A (pl)
CY (3) CY1113074T1 (pl)
DK (3) DK2061814T3 (pl)
ES (3) ES2387924T3 (pl)
HK (3) HK1173161A1 (pl)
HR (2) HRP20120683T1 (pl)
HU (1) HUE034263T2 (pl)
IL (1) IL197928A (pl)
LT (1) LT2845866T (pl)
MA (1) MA30910B1 (pl)
MX (1) MX2009003938A (pl)
NO (1) NO20092052L (pl)
NZ (1) NZ576132A (pl)
PE (2) PE20121023A1 (pl)
PL (3) PL2061814T3 (pl)
PT (3) PT2061814E (pl)
RS (2) RS53942B1 (pl)
RU (2) RU2639543C9 (pl)
SI (2) SI2845866T1 (pl)
TW (1) TWI428347B (pl)
WO (1) WO2008052187A2 (pl)
ZA (1) ZA201002209B (pl)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
EP2061814B1 (en) 2006-10-27 2012-06-06 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
US8541178B2 (en) * 2008-05-13 2013-09-24 Genentech, Inc. Analysis of antibody drug conjugates by bead-based affinity capture and mass spectrometry
CN107184976A (zh) * 2008-11-20 2017-09-22 弗·哈夫曼-拉罗切有限公司 治疗性蛋白质制剂
CN102348715B (zh) 2009-02-03 2017-12-08 阿穆尼克斯运营公司 延伸重组多肽和包含该延伸重组多肽的组合物
JP2012531212A (ja) 2009-07-03 2012-12-10 アビペップ ピーティーワイ リミテッド イムノコンジュゲート及びその作製方法
SG181814A1 (en) * 2009-12-23 2012-07-30 Avipep Pty Ltd Immuno-conjugates and methods for producing them 2
US9725500B2 (en) * 2010-03-02 2017-08-08 Seattle Genetics, Inc. Methods for screening antibodies
KR20130098165A (ko) * 2010-06-03 2013-09-04 제넨테크, 인크. 항체 및 면역접합체의 이뮤노-ｐｅｔ 영상화 및 그의 용도
EP2579887B1 (de) 2010-06-10 2014-11-12 Seattle Genetics, Inc. Neue auristatin-derivate und ihre verwendung
CN106084053B (zh) * 2010-06-15 2020-01-17 根马布股份公司 针对组织因子的人抗体药物缀合物
LT2621526T (lt) 2010-09-29 2018-09-25 Agensys, Inc. Antikūno-vaisto konjugatai (adc), kurie jungiasi prie 191p4d12 baltymų
ES2553874T3 (es) 2010-09-29 2015-12-14 Seattle Genetics, Inc. N-Carboxialquil-auristatinas y su uso
CN101942026B (zh) * 2010-10-14 2014-08-27 成都正能生物技术有限责任公司 长效干扰素融合蛋白及其用途
AR083819A1 (es) 2010-11-10 2013-03-27 Genentech Inc UN ANTICUERPO QUE SE UNE A BACE1 (ENZIMA 1 DE DISOCIACION DE PROTEINA PRECURSORA DEL AMILOIDE DE SITIO b), METODOS Y COMPOSICIONES PARA INMUNOTERAPIA PARA ENFERMEDAD NEURAL
ES2718846T3 (es) 2010-11-12 2019-07-04 Univ Pennsylvania Antígenos de próstata consenso, molécula de ácido nucleico que los codifica y la vacuna y usos que los comprenden
RU2440142C1 (ru) * 2011-02-07 2012-01-20 Общество С Ограниченной Ответственностью "Онкомакс" Антитело, останавливающее или замедляющее рост опухоли (варианты), способ подавления роста опухоли, способ диагностики злокачественных образований
CN103764667B (zh) 2011-03-16 2017-06-20 西雅图基因公司 N‑羧烷基耳他汀类及其应用
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
WO2012171020A1 (en) 2011-06-10 2012-12-13 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
WO2013033359A1 (en) * 2011-08-31 2013-03-07 The Trustees Of The University Of Pennsylvania Carbon nanotube biosensors and related methods
US20130116404A1 (en) 2011-11-08 2013-05-09 Case Western Reserve University Targeted non-invasive imaging probes of egfr expressing cells
KR101733853B1 (ko) 2011-11-17 2017-05-08 화이자 인코포레이티드 세포독성 펩티드 및 그의 항체 약물 접합체
AU2015264844B2 (en) * 2011-11-17 2016-09-01 Pfizer Inc. Cytotoxic peptides and antibody drug conjugates thereof
CA2854042A1 (en) * 2011-11-29 2013-06-06 Genentech, Inc. Compositions and methods for prostate cancer analysis
CN117462693A (zh) 2012-02-27 2024-01-30 阿穆尼克斯运营公司 Xten缀合组合物和制造其的方法
CA2869704A1 (en) 2012-04-04 2013-10-10 Perseus Proteomics Inc. Drug conjugate comprising anti-cdh3 (pcadherin) antibody
CN112587658A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
PL2887959T3 (pl) * 2012-08-23 2019-04-30 Agensys Inc Koniugaty leków i przeciwciał (adc), które wiążą białka 158p1d7
TW201431880A (zh) 2012-11-07 2014-08-16 Pfizer 抗切口３（ａｎｔｉ－ｎｏｔｃｈ３）抗體及抗體－藥物共軛體
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
PT2953976T (pt) 2013-02-08 2021-06-23 Novartis Ag Sítios específicos de modificação de anticorpos para preparar imunoconjugados
DK2961771T3 (da) 2013-02-26 2020-03-02 Roche Glycart Ag Bispecifikke, T-celle-aktiverende, antigenbindende molekyler, der er specifikke for CD3 og CEA
US10570151B2 (en) 2013-03-15 2020-02-25 Regeneron Pharmaceuticals, Inc. Biologically active molecules, conjugates thereof, and therapeutic uses
WO2014165818A2 (en) 2013-04-05 2014-10-09 T Cell Therapeutics, Inc. Compositions and methods for preventing and treating prostate cancer
WO2015031396A1 (en) 2013-08-26 2015-03-05 Regeneron Pharmaceuticals, Inc. Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses
AU2014324884B2 (en) * 2013-09-25 2020-03-26 Cytomx Therapeutics, Inc Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
KR102355745B1 (ko) 2013-10-11 2022-01-26 아사나 바이오사이언시스 엘엘씨 단백질-폴리머-약물 접합체
KR102087850B1 (ko) 2013-10-11 2020-03-12 메르사나 테라퓨틱스, 인코포레이티드 단백질-고분자-약물 접합체
CA2936377A1 (en) 2014-01-10 2015-07-16 Shanghai Birdie Biotech, Inc. Compounds and compositions for treating egfr expressing tumors
AU2015209154A1 (en) * 2014-01-24 2017-02-16 Genentech, Inc. Methods of using anti-STEAP1 antibodies and immunoconjugates
WO2015116933A2 (en) 2014-01-31 2015-08-06 Cytomx Therapeutics, Inc. Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
KR102462743B1 (ko) 2014-07-09 2022-11-02 버디 바이오파마슈티칼즈, 인크. 종양 치료용 항-pd-l1 조합
CN112587672A (zh) 2014-09-01 2021-04-02 博笛生物科技有限公司 用于***的抗-pd-l1结合物
US11415546B2 (en) 2014-09-05 2022-08-16 The Trustees Of The University Of Pennsylvania Volatile organic compound-based diagnostic systems and methods
US10400037B2 (en) * 2014-09-30 2019-09-03 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Binding molecules, especially antibodies, binding to L1CAM (CD171)
MX2017004103A (es) 2014-10-01 2017-07-07 Medimmune Ltd Proteinas de union especificas para el receptor 1 de lipoproteinas de baja densidad oxidadas de tipo lectina (lox1) y sus usos.
CN107108745B (zh) 2014-11-19 2021-01-12 基因泰克公司 抗bace1的抗体和其用于神经疾病免疫疗法的用途
JP6993228B2 (ja) 2014-11-19 2022-03-03 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体／抗ｂａｃｅ１多重特異性抗体および使用方法
MA41374A (fr) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
SG10202006863YA (en) 2015-02-16 2020-08-28 Lonza Ag Cl and/or ch1 mutated antibodies for drug conjugation
WO2016205176A1 (en) 2015-06-15 2016-12-22 Genentech, Inc. Antibodies and immunoconjugates
AR106199A1 (es) * 2015-10-02 2017-12-20 Hoffmann La Roche Moléculas de unión a antígeno biespecíficas activadoras de células t
JP7044700B2 (ja) * 2015-10-02 2022-03-30 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性抗ｃｅａｘｃｄ３ ｔ細胞活性化抗原結合分子
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
CN106943598A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于***的抗-her2组合
CN115554406A (zh) 2016-01-07 2023-01-03 博笛生物科技有限公司 用于***的抗-cd20组合
CN106943597A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于***的抗-egfr组合
CA3006529A1 (en) 2016-01-08 2017-07-13 F. Hoffmann-La Roche Ag Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
BR112018014759B1 (pt) 2016-01-25 2024-02-27 Regeneron Pharmaceuticals, Inc Compostos derivados de maitasinoide e seus conjugados, composição compreendendo os mesmos, seus métodos de fabricação e uso
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
CA3045466A1 (en) 2016-12-01 2018-06-07 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
CN108271193B (zh) * 2016-12-30 2020-07-10 ***通信集团公司 一种业务容灾探测方法、mme及sgw
SG11201907288RA (en) 2017-02-28 2019-09-27 Seattle Genetics Inc Cysteine mutated antibodies for conjugation
CN110494452B (zh) 2017-04-03 2023-08-25 豪夫迈·罗氏有限公司 结合steap-1的抗体
CN108794467A (zh) 2017-04-27 2018-11-13 博笛生物科技有限公司 2-氨基-喹啉衍生物
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
CA3098491A1 (en) * 2017-06-20 2018-12-27 Sichuan Baili Pharm Co. Ltd Screening of fixed-point coupling sites of cysteine-modified antibody-toxin conjugate (tdc)
WO2018232725A1 (en) 2017-06-23 2018-12-27 Birdie Biopharmaceuticals, Inc. PHARMACEUTICAL COMPOSITIONS
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
WO2019183633A1 (en) 2018-03-23 2019-09-26 Case Western Reserve Univeristy Psma targeted conjugate compounds and uses thereof
JP7390315B2 (ja) 2018-06-01 2023-12-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 スプライシング調節薬抗体－薬物コンジュゲート及びその使用方法
WO2019243825A1 (en) 2018-06-21 2019-12-26 Curadev Pharma Limited Small molecule modulators of human sting, conjugates and therapeutic applications
SG11202013138RA (en) * 2018-07-02 2021-01-28 Amgen Inc Anti-steap1 antigen-binding protein
KR20210033025A (ko) * 2018-07-18 2021-03-25 암젠 인크 Steap1에 대한 키메라 수용체 및 이의 사용 방법
WO2020041532A1 (en) * 2018-08-21 2020-02-27 Sf17 Therapeutics, Inc. Compositions and methods for treating progressive neurodegenerative diseases
CN110872324B (zh) * 2018-08-29 2021-09-14 中国科学院上海药物研究所 奥沙利铂偶联前药、其制备方法及用途
JP2022502517A (ja) * 2018-10-15 2022-01-11 ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System ヒトｄｉｃｋｋｏｐｆ３に対するモノクローナル抗体およびその使用方法
AU2019397062A1 (en) 2018-12-13 2021-05-06 Eisai R&D Management Co., Ltd. Herboxidiene antibody-drug conjugates and methods of use
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
KR20220044753A (ko) 2019-07-25 2022-04-11 큐라데브 파마 프라이버트 리미티드 아세틸 조효소 a 신테타제 단쇄 2(acss2)의 소분자 억제제
AU2020343652A1 (en) * 2019-09-05 2022-03-24 Memorial Sloan Kettering Cancer Center Anti-STEAP1 antibodies and uses thereof
CN111073892B (zh) * 2019-10-30 2023-11-17 广西科学院 一种识别石斑鱼虹彩病毒感染细胞的核酸适配体及其构建方法和应用
AU2021349385A1 (en) * 2020-09-28 2023-05-25 Seagen Inc. Humanized anti-liv1 antibodies for the treatment of cancer
WO2023154890A2 (en) * 2022-02-11 2023-08-17 Fred Hutchinson Cancer Center Chimeric antigen receptors binding steap1
WO2023161457A1 (en) 2022-02-27 2023-08-31 Evobright Gmbh Bispecific antibodies against cd277 and a tumor-antigen
GB202208119D0 (en) 2022-06-01 2022-07-13 Univ Oslo Hf Anti-steap1 car

Family Cites Families (224)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3720760A (en) 1968-09-06 1973-03-13 Pharmacia Ab Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CH605550A5 (pl) * 1972-06-08 1978-09-29 Research Corp
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
AU3934085A (en) 1984-01-30 1985-08-09 Icrf Patents Ltd. Improvements relating to growth factors
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5342606A (en) 1984-10-18 1994-08-30 Board Of Regents, The University Of Texas System Polyazamacrocyclic compounds for complexation of metal ions
US5316757A (en) 1984-10-18 1994-05-31 Board Of Regents, The University Of Texas System Synthesis of polyazamacrocycles with more than one type of side-chain chelating groups
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5091178A (en) 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5079233A (en) 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
WO1991000360A1 (en) 1989-06-29 1991-01-10 Medarex, Inc. Bispecific reagents for aids therapy
US6020145A (en) 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
WO1991005264A1 (en) 1989-09-29 1991-04-18 Oncogenetics Partners Detection and quantification of neu related proteins in the biological fluids of humans
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1991010741A1 (en) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
AU8295491A (en) 1990-06-29 1992-01-23 Biosource Technologies Incorporated Melanin production by transformed microorganisms
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5264365A (en) 1990-11-09 1993-11-23 Board Of Regents, The University Of Texas System Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
US5508192A (en) 1990-11-09 1996-04-16 Board Of Regents, The University Of Texas System Bacterial host strains for producing proteolytically sensitive polypeptides
EP0564531B1 (en) 1990-12-03 1998-03-25 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
DK0605522T3 (da) 1991-09-23 2000-01-17 Medical Res Council Fremgangsmåde til fremstilling af humaniserede antistoffer
US5362852A (en) 1991-09-27 1994-11-08 Pfizer Inc. Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5428139A (en) 1991-12-10 1995-06-27 The Dow Chemical Company Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals
US5739294A (en) 1991-12-10 1998-04-14 The Dow Chemical Company Bicyclopol yazamacrocyclophosphonic acid complexes for use as contrast agents
US5480990A (en) 1991-12-10 1996-01-02 The Dow Chemical Company Bicyclopolyazamacrocyclocarboxylic acid complexes for use as contrast agents
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
DE69334255D1 (de) 1992-02-06 2009-02-12 Novartis Vaccines & Diagnostic Marker für Krebs und biosynthetisches Bindeprotein dafür
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
US5489525A (en) 1992-10-08 1996-02-06 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibodies to prostate cells
EP0752248B1 (en) 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5385893A (en) 1993-05-06 1995-01-31 The Dow Chemical Company Tricyclopolyazamacrocyclophosphonic acids, complexes and derivatives thereof, for use as contrast agents
US5462725A (en) 1993-05-06 1995-10-31 The Dow Chemical Company 2-pyridylmethylenepolyazamacrocyclophosphonic acids, complexes and derivatives thereof, for use as contrast agents
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
EP0731106B1 (en) 1993-10-01 2004-11-17 Teikoku Hormone Mfg. Co., Ltd. Dolastatin derivatives
EP0679716A4 (en) 1993-11-12 1999-06-09 Kenichi Matsubara GENE SIGNATURE.
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5639635A (en) 1994-11-03 1997-06-17 Genentech, Inc. Process for bacterial production of polypeptides
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US5834456A (en) 1996-02-23 1998-11-10 The Dow Chemical Company Polyazamacrocyclofluoromonoalkylphosphonic acids, and their complexes, for use as contrast agents
US6027888A (en) 1996-04-05 2000-02-22 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide-bond containing eukaryotic proteins in bacterial cells
US5859045A (en) * 1996-05-08 1999-01-12 Novo Nordisk A/S Novo Alle Crystalline -! 3R 4R-trans-7 methoxy 2,2-dimethyl1-3-phenyl 1-4 4-12 pyrrolidin-1 -Y1!ethoxyl 1!chromane hydrogen fumarate
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US5824504A (en) 1996-09-26 1998-10-20 Elshourbagy; Nabil A. Human 7-transmembrane receptor and DNA
AU5243198A (en) 1996-10-30 1998-05-22 Uab Research Foundation, The Enhancement of tumor cell chemosensitivity and radiosensitivity using single chain intracellular antibodies
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
ATE302414T1 (de) 1997-02-25 2005-09-15 Corixa Corp Verbindungen zur immundiagnose von prostatakrebs und deren verwendung
TR199902053T2 (xx) 1997-02-25 2000-04-21 Corixa Corporation Prostat kanserinin immunoterapisine y�nelik bile�ikler ve bunlar�n kullan�lmas�na matuf metodlar.
US6800746B2 (en) * 1997-02-25 2004-10-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO2003004622A2 (en) 2001-03-21 2003-01-16 Human Genome Sciences, Inc. Human secreted proteins
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
JP2002516572A (ja) 1997-05-23 2002-06-04 バイオジェン，インコーポレイテッド 組織の再生の調節
US6083715A (en) 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
CA2293829C (en) 1997-06-24 2011-06-14 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
WO1999006548A2 (en) 1997-08-01 1999-02-11 Genset 5'ESTs FOR NON TISSUE SPECIFIC SECRETED PROTEINS
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
JPH11164691A (ja) 1997-10-03 1999-06-22 Rikagaku Kenkyusho 胚盤胞ｃＤＮＡ
US20030060612A1 (en) * 1997-10-28 2003-03-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU759779B2 (en) 1997-10-31 2003-05-01 Genentech Inc. Methods and compositions comprising glycoprotein glycoforms
DK1068241T3 (da) 1998-04-02 2008-02-04 Genentech Inc Antistofvarianter og fragmenter deraf
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
US6048970A (en) 1998-05-22 2000-04-11 Incyte Pharmaceuticals, Inc. Prostate growth-associated membrane proteins
US20030064397A1 (en) * 1998-05-22 2003-04-03 Incyte Genomics, Inc. Transmembrane protein differentially expressed in prostate and lung tumors
US20030149531A1 (en) * 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
JP4855577B2 (ja) * 1998-06-01 2012-01-18 アジェンシス，インコーポレイテッド ヒト癌で発現される新規蛇行性膜貫通抗原およびその使用
US6833438B1 (en) * 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
WO2001040276A2 (en) 1999-12-06 2001-06-07 Agensys, Inc Serpentine transmembrane antigens expressed in human prostate cancers and uses thereof
KR20070112860A (ko) 1998-07-14 2007-11-27 코릭사 코포레이션 전립선 종양 단백질의 분리된 면역원성 부위 및 이를사용하여 전립선암을 진단하는 방법
JP2002532083A (ja) 1998-12-17 2002-10-02 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ４７個のヒト分泌タンパク質
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
PT1914244E (pt) 1999-04-09 2013-07-26 Kyowa Hakko Kirin Co Ltd Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico
CA2372053C (en) * 1999-04-28 2008-09-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
EP1189917A4 (en) 1999-06-11 2003-11-05 Human Genome Sciences Inc 48 HUMAN SECRETED PROTEINS
BR122014028365B8 (pt) 1999-06-25 2021-07-06 Genentech Inc artigo industrializado compreendendo um primeiro recipiente que compreende uma composição de humab4d5-8 nele contida e um segundo recipiente que compreende uma composição rhumab 2c4 nele contida
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
AU6906800A (en) 1999-08-17 2001-03-13 Incyte Genomics, Inc. Membrane associated proteins
GB2354821A (en) 1999-09-29 2001-04-04 Dine O Quick Threshold crossing counter
AU7994200A (en) 1999-10-04 2001-05-10 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
UA74798C2 (uk) * 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
JP4668498B2 (ja) 1999-10-19 2011-04-13 協和発酵キリン株式会社 ポリペプチドの製造方法
US6824780B1 (en) 1999-10-29 2004-11-30 Genentech, Inc. Anti-tumor antibody compositions and methods of use
US6372907B1 (en) 1999-11-03 2002-04-16 Apptera Corporation Water-soluble rhodamine dye peptide conjugates
JP2004537252A (ja) 1999-11-12 2004-12-16 コリクサ コーポレイション 前立腺癌の治療及び診断のための組成物及び方法
US20040001827A1 (en) 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
JP2003518075A (ja) 1999-12-24 2003-06-03 ジェネンテック・インコーポレーテッド 生理活性化合物の消失半減期延長のための方法及び組成物
HUP0203968A3 (en) 2000-01-14 2004-09-28 Corixa Corp Seattle Compositions and methods for the therapy and diagnosis of prostate cancer
WO2001057190A2 (en) 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides
AU2001233114A1 (en) 2000-02-04 2001-08-14 Aeomica, Inc. Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
AU2001241541A1 (en) 2000-02-17 2001-08-27 Millennium Predictive Medicine, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
EP1268526A4 (en) 2000-03-24 2004-09-08 Fahri Saatcioglu NEW PROSTATE-SPECIFIC AND TESTIS-SPECIFIC NUCLEIC ACID MOLECULES, POLYPEPTIDES AND DIAGNOSTIC AND THERAPEUTIC PROCEDURES
AU2001249549A1 (en) 2000-03-27 2001-10-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
JP2004509612A (ja) 2000-06-05 2004-04-02 アバロン　ファーマシューティカルズ ガン遺伝子決定および特徴的な遺伝子群を用いた治療用スクリーニング
AU2001268259A1 (en) 2000-06-09 2001-12-24 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
EP1305450A2 (en) 2000-07-28 2003-05-02 Compugen Inc. Oligonucleotide library for detecting rna transcripts and splice variants that populate a transcriptome
CA2420140A1 (en) 2000-08-24 2002-02-28 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
MXPA03003151A (es) 2000-10-13 2003-08-19 Eos Biotechnology Inc Metodos de diagnostico de cancer de prostata, composiciones y metodos para seleccionar moduladores de cancer de prostata.
EP1661986A1 (en) 2000-11-17 2006-05-31 Nuvelo, Inc. Nucleic acids and polypeptides enocoded thereby that are member of the kallikrein gene familyNovel nucleic acids and polypeptides
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
ES2649037T3 (es) 2000-12-12 2018-01-09 Medimmune, Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
WO2002057303A2 (en) 2001-01-12 2002-07-25 Hybrigenics Protein-protein interactions between shigella flexneri polypeptides and mammalian polypeptides
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
WO2003009814A2 (en) 2001-07-25 2003-02-06 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
CN1555411A (zh) 2001-08-03 2004-12-15 ���迨�����＼���ɷݹ�˾ 抗体-依赖性细胞毒性增大的抗体糖基化变体
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
EP2287186B1 (en) * 2001-09-06 2014-12-31 Agensys, Inc. Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
EP1443961B1 (en) 2001-10-25 2009-05-06 Genentech, Inc. Glycoprotein compositions
EP1308459A3 (en) 2001-11-05 2003-07-09 Research Association for Biotechnology Full-length cDNA sequences
CA2467242A1 (en) 2001-11-20 2003-05-30 Seattle Genetics, Inc. Treatment of immunological disorders using anti-cd30 antibodies
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
JP4628679B2 (ja) 2002-04-09 2011-02-09 協和発酵キリン株式会社 Ｇｄｐ−フコースの輸送に関与する蛋白質の活性が低下または欠失した細胞
AU2003236018A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
US7691568B2 (en) 2002-04-09 2010-04-06 Kyowa Hakko Kirin Co., Ltd Antibody composition-containing medicament
CA2481925A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for patients having human fc.gamma.riiia
JPWO2003085107A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 ゲノムが改変された細胞
CN100495938C (zh) 2002-06-20 2009-06-03 施耐普特拉克股份有限公司 减少组合gps接收机和通信***中的交叉干扰
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
US20050180972A1 (en) 2002-07-31 2005-08-18 Wahl Alan F. Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders
EP2357006B1 (en) 2002-07-31 2015-09-16 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004042017A2 (en) 2002-10-31 2004-05-21 Genentech, Inc. Methods and compositions for increasing antibody production
AU2003282624A1 (en) 2002-11-14 2004-06-03 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
EP1572744B1 (en) 2002-12-16 2010-06-09 Genentech, Inc. Immunoglobulin variants and uses thereof
CA2513113A1 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
WO2005035586A1 (ja) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. 融合蛋白質組成物
EP1705251A4 (en) 2003-10-09 2009-10-28 Kyowa Hakko Kirin Co Ltd PROCESS FOR PRODUCING ANTIBODY COMPOSITION BY RNA INHIBITION OF FUNCTION OF $ G (A) 1,6-FUCOSYLTRANSFERASE
RS55723B1 (sr) 2003-11-05 2017-07-31 Roche Glycart Ag Molekuli koji se vezuju za antigen sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom
BR122018071968B8 (pt) 2003-11-06 2021-07-27 Seattle Genetics Inc conjugado de anticorpo-droga, composição farmacêutica, artigo de manufatura e uso de um conjugado de anticorpo-droga
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
EP1718667B1 (en) 2004-02-23 2013-01-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
BRPI0418766B8 (pt) * 2004-04-22 2021-05-25 Agensys Inc anticorpo ou seu fragmento, vetor, composição farmacêutica, ensaio e método para detectar a presença de proteína steap-1, bem como método para distribuir um agente citotóxico ou um agente de diagnóstico
WO2006000020A1 (en) 2004-06-29 2006-01-05 European Nickel Plc Improved leaching of base metals
NZ580115A (en) 2004-09-23 2010-10-29 Genentech Inc Cysteine engineered antibody light chains and conjugates
EP4026840A1 (en) 2005-07-18 2022-07-13 Seagen Inc. Beta-glucuronide-linker drug conjugates
EP2061814B1 (en) 2006-10-27 2012-06-06 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
CN107184976A (zh) 2008-11-20 2017-09-22 弗·哈夫曼-拉罗切有限公司 治疗性蛋白质制剂

Also Published As

Publication number Publication date
AU2007308792A1 (en) 2008-05-02
US8436147B2 (en) 2013-05-07
DK2502938T3 (en) 2015-04-20
RU2013115284A (ru) 2014-10-10
HK1208228A1 (en) 2016-02-26
IL197928A (en) 2014-02-27
US9593167B2 (en) 2017-03-14
PT2502938E (pt) 2015-06-05
CA2667019A1 (en) 2008-05-02
CR10734A (es) 2009-06-25
RU2639543C9 (ru) 2018-06-14
DK2061814T3 (da) 2012-08-27
ES2387924T3 (es) 2012-10-04
RU2009119976A (ru) 2010-12-10
BRPI0717638A2 (pt) 2013-11-12
EP2061814B1 (en) 2012-06-06
PE20081266A1 (es) 2008-10-04
RU2639543C2 (pl) 2017-12-21
AU2007308792B2 (en) 2013-01-24
CA2667019C (en) 2016-03-29
IL197928A0 (en) 2011-08-01
ES2636089T3 (es) 2017-10-05
US20170234883A1 (en) 2017-08-17
PL2061814T3 (pl) 2012-10-31
MX2009003938A (es) 2009-04-24
US20180106809A1 (en) 2018-04-19
US20150166674A1 (en) 2015-06-18
TW200825105A (en) 2008-06-16
CY1119102T1 (el) 2018-03-07
KR101541550B1 (ko) 2015-08-04
AU2007308792A2 (en) 2009-06-25
KR20090078360A (ko) 2009-07-17
RU2483080C2 (ru) 2013-05-27
US8889847B2 (en) 2014-11-18
PE20121023A1 (es) 2012-08-06
KR20140116546A (ko) 2014-10-02
NZ576132A (en) 2012-04-27
HK1173161A1 (en) 2013-05-10
ES2535637T3 (es) 2015-05-13
CY1116261T1 (el) 2017-02-08
PT2061814E (pt) 2012-09-10
EP2502938A2 (en) 2012-09-26
PL2502938T3 (pl) 2015-07-31
HUE034263T2 (en) 2018-02-28
SI2502938T1 (sl) 2015-05-29
LT2845866T (lt) 2017-07-10
HRP20120683T1 (hr) 2012-09-30
EP2061814A2 (en) 2009-05-27
WO2008052187A2 (en) 2008-05-02
US20090280056A1 (en) 2009-11-12
SI2845866T1 (sl) 2017-07-31
HRP20150508T1 (hr) 2015-06-19
EP2502938A3 (en) 2013-01-23
CO6180431A2 (es) 2010-07-19
RS52452B (en) 2013-02-28
EP2502938B1 (en) 2015-02-18
TWI428347B (zh) 2014-03-01
AR063532A1 (es) 2009-01-28
US20130316402A1 (en) 2013-11-28
NO20092052L (no) 2009-07-24
CY1113074T1 (el) 2016-04-13
EP2845866B1 (en) 2017-05-03
PT2845866T (pt) 2017-08-09
DK2845866T3 (en) 2017-07-10
EP2845866A1 (en) 2015-03-11
RS53942B1 (en) 2015-08-31
MA30910B1 (fr) 2009-11-02
PL2845866T3 (pl) 2017-10-31
WO2008052187A3 (en) 2008-07-17
ZA201002209B (en) 2012-08-29

Similar Documents

Publication Publication Date Title
HK1131626A1 (en) Antibodies and immunoconjugates and uses therefor
MY148635A (en) Anti-tat226 antibodies and immunoconjugates
WO2007140371A8 (en) Antibodies and immunoconjugates and uses therefor
TWI339962B (en) Source apparatus, destination apparatus, and intermediate apparatus
ZA200809776B (en) Antibodies and immunoconjugates and uses therefor
SI2061814T1 (sl) Protitelesa in imunokonjugati in njihove uporabe
IL183231A0 (en) Substance source
ZA200804868B (en) Anti-OX40L antibodies and methods using same
MY150643A (en) Methods and compositions for targeting hepsin
CR20140126A (es) Anticuerpos anti-tat226 e inmunoconjugados